Vycellix

Read More

Vycellix Founders Awarded Major Swedish Grant to Establish NextGen-NK

Vycellix Founders Awarded Innovation Grant by Sweden’s Vinnova to Establish New World-Class Research Environment on Development of Next-Generation Natural Killer Cell-based Cancer Immunotherapy Vycellix included as collaborative partner within the Center’s research constellation of prestigious academic & industry partners TAMPA, FLORIDA & STOCKHOLM, SWEDEN – June 27, 2019 – Vycellix™, Inc. today announced that the […]

Read More

Vycellix Announces Formation of Scientific Advisory Board

SAB Comprised of Key Opinion Leaders Advancing Next-Generation Cell & Gene-based Immuno-Oncology Therapeutic Platforms TAMPA, FLORIDA & STOCKHOLM, SWEDEN – June 25, 2019 – Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned Karolinska Institutet, has appointed the inaugural members of its Scientific Advisory Board (SAB). Vycellix’s SAB […]

Read More

Vycellix CEO to Present Strategies for Enhancing Next-Generation NK Cell Cancer Therapy at Innate Killer Summit

TAMPA, FLORIDA & STOCKHOLM, SWEDEN – March 15, 2019 – Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned Karolinska Institutet, will present at the Innate Killer Summit 2019 to be held in San Diego, March 20-21. On Wednesday, March 20th at 4:20pm PT, Vycellix’s founding CEO, Evren […]

Read More

Vycellix and Moffitt Cancer Center Announce a Collaborative Research Study to Evaluate Novel Product Candidates for Improving Adoptive Cell Immunotherapies for Cancer

Studies designed to enhance T cell and NK cell potencies through improved genetic modification and increased cytolytic granules SARASOTA and TAMPA, Fla. – Feb. 27, 2017 – Vycellix, Inc., a biopharmaceutical company advancing innovative small molecules to enhance cellular therapies, facilitate manufacturing processes and optimize human immune response against disease, today announced that it has […]

Read More

Vycellix’s CEO to Present Novel Approaches to Adoptive Cancer Immunotherapy at Innate Killer Summit

New Products Enhance Genetic Modification of Lymphocytes  and Significantly Amplify Cancer Killing Capacity Sarasota, Fla. – May 2, 2016 – Vycellix, Inc., a privately-held biotechnology company advancing novel products capable of optimizing human immune response against disease with a focus on cancers, today announced that its CEO, Evren Alici, M.D., Ph.D., will present at the […]